Advanced neuroimaging provides an in-vivo exploration into diseases such as multiple sclerosis (MS). Given the ability to visualize T2-hyperintense lesions and gadolinium-enhancement, magnetic resonance imaging (MRI) has been the traditional imaging modality of choice among MS researchers and clinicians. Positron emission tomography (PET) is widely accepted within the field of oncology and more recently, actively utilized for basic research, clinical trials, and clinical management for a number of psychiatric and neurodegenerative diseases. In MS, PET has only been more actively explored over the past few years, although, [ 11 C]PK11195 (first generation TSPO ligand) was first used to evaluate MS lesions nearly 30 years ago. 1 The delay to embrace PET within the MS community is reasonable considering the complexities of PET and relative simplicity of MRI; however, as an ever-evolving field with new ligands being developed, a discussion is warranted to assess the benefits and feasibility of PET to explore pathological mechanisms of disease in MS.
Bodini and Stankoff support the argument that PET is essential to move the field of MS forward. These authors highlight a high level of specificity gained by PET to assess activity of the innate immune system, detect early signs of neurodegeneration, and explore myelin dynamics. 2 More recently, PET ligands are being developed to explore altered synaptic function, which has gained increasing attention as a potential pathological substrate of cognitive dysfunction in MS. 3 These authors propose that PET will provide deep phenotyping of brain pathology and can be utilized to quantify an individual patients' remyelination profile. The alternative viewpoint, presented by Preziosa et al. 4 argues that most of the PET ligands, utilized for MS, have a limited cellular target and lack disease specificity. Importantly, Preziosa et al. highlight the complexity of PET, as compared to MRI, with a focus on the complicated quantification, limited safety data and poor feasibility for serial imaging.
Over the years, TSPO radioligands have improved their level of specificity, yet still remain limited by heterogeneous binding due to genetic polymorphisms. A relatively new TSPO ligand, [ 11 C]ER176, has been reported to bind all three genotypes (high, mixed, and low affinity binder), thus providing a significant advancement. 5 Furthermore, a new generation of inflammatory targets are emerging, such as purinergic receptors (P2X7, P2Y212), adenosine receptors (A2A), and cannabinoid receptor (CB2), which may provide a more specific and complex analysis of the immune response in MS as compared to TSPO ligands. 6 Hence, as ligand development continues, there lies a potential to improve the level of cellular specificity.
The lack of consensus regarding TSPO quantification has further complicated the acceptance of PET Visit SAGE journals online journals.sagepub.com/ home/msj SAGE journals and limited comparisons among studies. Multiple quantification approaches have been utilized in MS, such as image-derived input function, cluster analysis, pseudo-reference region as well as traditional arterial blood sampling. Ideally, an avoidance of arterial sampling would increase the feasibility of PET; however, non-invasive methods should not be utilized at the expense of accurate quantification. Each method has different advantages and disadvantages wherein the most suitable approach will depend on the study conditions. 7, 8 As we move forward with novel inflammatory targets, efforts should be taken to determine the most effective quantification method for each individual ligand.
The feasibility of utilizing a 11 C as radioisotope is clearly limited by a short-half-life and the requirement of an on-site cyclotron. As fluorinated ( 18 F) radiotracers are developed, large multi-center studies, similar to those for oncology and Alzheimer's disease, may be feasible in MS. However, given the exposure to ionized radiation associated with PET, the safety concern for serial imaging needs to be addressed. All investigators should have PET imaging protocols reviewed by their institutional radiation safety committee to ensure standard guidelines are met. Considering the unknown safety risk of serial PET imaging, we wouldn't expect PET to replace MRI for the ongoing clinical management of MS patients.
In conclusion, PET provides unique opportunity to explore disease mechanisms in MS; however, clearly, limitations remain and advancements are required prior to a broader utilization and acceptance.
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